Nexstim Plc, a medical technology company, (NXTMH) Fair Value & Analysis
Healthcare · FI · Market cap €72.9M
Fair value as of: Jul 18, 2026
From 14 valuation models · updated 23 days ago
Share price −3.9% over the past month.
Below-average quality, and screening another 88% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (€1.43). The favourable scenario is already priced in.
- Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range €2.18 – €16.40 · fair‑value band €0.8585 – €1.43 · the €9.44 price screens above the €1.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 18, 2026.
Analysis
Nexstim Plc, a medical technology company, (NXTMH) currently trades at €9.44, while our model-based Fair Value estimate is €1.15, implying the stock looks roughly 87.8% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Nexstim Plc, a medical technology company, generated revenue of €12.4M at a net margin of 4.6%. Revenue grew 12.5% year over year. It earns a return on equity of 14.6%. Net debt stands at €1.5M. Fundamentals as of Jul 18, 2026
Our scenario range runs from €0.8585 (bear case) to €1.43 (bull case); at €9.44, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 21% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -88%, NXTMH screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Growth Earnings (€2.17) versus Asset-Based (€0.3900). Highest evidence: ROIC Compounder (72).
Notify me when NXTMH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally.
Full company description
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilateral neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb. The company markets and sells its diagnostics systems to universities and teaching hospitals. It has an exclusive collaboration with Sinaptica Therapeutics, Inc. for the development, manufacture, and delivery of precision neuromodulation system for the treatment of Alzheimer's disease and mild cognitive impairment; and a development and distribution collaboration with Brainlab AG for motor and speech mapping systems. The company was incorporated in 2000 and is headquartered in Helsinki, Finland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Nexstim Plc, a medical technology company, reported revenue of €11.0M in FY2025 versus €6.4M in FY2021, a compound +14.4%/yr. Reported net income was €573K in FY2025.
NXTMH screens 88% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Nexstim Plc, a medical technology company, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Nexstim Plc, a medical technology company, (NXTMH) overvalued or undervalued?
What is the fair value of NXTMH?
What is the quality score of NXTMH?
What is the revenue of Nexstim Plc, a medical technology company, (NXTMH)?
What is the net profit margin of NXTMH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Nexstim Plc, a medical technology company, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.